Ramipril

Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

ACE InhibitorsRamipril1.25mg-5mg PO Q24HAdminister Post HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
416358-1014-1673 (ramiprilat)1.223.3Minimal (low flux)

References:

  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00178
  • Fillastre J, Baguet J, Dubois D, et al. Kinetics, Safety, and Efficacy of Ramipril after Long-Term Administration in Hemodialyzed Patients. Journal of Cardiovascular Pharmacology. 1996;27(2):269-274.
  • Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
  • Zheng S, Nath V, Coyne D. ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. American journal of nephrology. 2007;27(5):522-9.